Literature DB >> 15097887

Clinical phenotype as a prognostic factor in Stargardt disease.

Kean T Oh1, Richard G Weleber, Dawn M Oh, Andrea M Billingslea, Justin Rosenow, Edwin M Stone.   

Abstract

PURPOSE: To determine the prognostic significance of widespread flecks, described as fundus flavimaculatus, in patients with Stargardt disease.
DESIGN: Historical cohort study. SUBJECTS AND METHODS: Patients with Stargardt disease were identified by searching preexisting databases at the University of Iowa and Oregon Health Sciences University. The medical records of these patients were evaluated for the validity of the diagnosis, initial and final visual acuity, length of follow-up, and initial and final phenotype. Phenotype was graded as I, II, or III on the basis of the distribution of flecks and the extent of atrophy. The relationship between final visual acuity and final clinical appearance (phenotype I versus II versus III) was evaluated controlling for length of follow-up and age using a Cochran-Mantel-Haenszel test. The clinical progression of visual acuity loss for each phenotype was analyzed using life tables and Kaplan-Meier survival analysis for age and length of follow-up effects.
RESULTS: A total of 214 patients were confirmed to have Stargardt disease; 131 patients were seen at multiple visits. Eighty-two patients were identified with phenotype I, 62 with phenotype II, and 70 with phenotype III. The final visual outcome was significantly better for patients whose ophthalmoscopic abnormalities were limited to the macula (phenotype I): 80 of 82 patients with phenotype I (97.6%) maintained 20/200 or better visual acuity in at least one eye as compared to 40/62 (64.5%) patients with phenotype II and 13/70 (18.6%) patients with phenotype III (P < 0.0001). Survival analysis showed a similarly significant difference in the survival probabilities (likelihood of maintaining 20/200 or better vision) for the three phenotypes considered over age and over follow-up length (P < 0.0001), with phenotypes II and III demonstrating significantly more deterioration in vision over time.
CONCLUSIONS: The presence of midperipheral flecks, especially early in life, carries a poorer visual prognosis for patients with Stargardt disease than when disease is limited to the macula. The development of midperipheral flecks is an indicator of more extensive fundus involvement and thus poorer long-term visual prognosis.

Entities:  

Mesh:

Year:  2004        PMID: 15097887     DOI: 10.1097/00006982-200404000-00011

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  9 in total

1.  The spectrum of retinal phenotypes caused by mutations in the ABCA4 gene.

Authors:  B Jeroen Klevering; August F Deutman; Alessandra Maugeri; Frans P M Cremers; Carel B Hoyng
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-12-22       Impact factor: 3.117

2.  Predicting Progression of ABCA4-Associated Retinal Degenerations Based on Longitudinal Measurements of the Leading Disease Front.

Authors:  Artur V Cideciyan; Malgorzata Swider; Sharon B Schwartz; Edwin M Stone; Samuel G Jacobson
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-09       Impact factor: 4.799

3.  ABCA4 disease progression and a proposed strategy for gene therapy.

Authors:  Artur V Cideciyan; Malgorzata Swider; Tomas S Aleman; Yaroslav Tsybovsky; Sharon B Schwartz; Elizabeth A M Windsor; Alejandro J Roman; Alexander Sumaroka; Janet D Steinberg; Samuel G Jacobson; Edwin M Stone; Krzysztof Palczewski
Journal:  Hum Mol Genet       Date:  2008-12-12       Impact factor: 6.150

4.  Macular function and morphologic features in juvenile stargardt disease: longitudinal study.

Authors:  Francesco Testa; Paolo Melillo; Valentina Di Iorio; Ada Orrico; Marcella Attanasio; Settimio Rossi; Francesca Simonelli
Journal:  Ophthalmology       Date:  2014-08-02       Impact factor: 12.079

5.  Clinical phenotypes and prognostic full-field electroretinographic findings in Stargardt disease.

Authors:  Sarwar Zahid; Thiran Jayasundera; William Rhoades; Kari Branham; Naheed Khan; Leslie M Niziol; David C Musch; John R Heckenlively
Journal:  Am J Ophthalmol       Date:  2012-12-05       Impact factor: 5.258

6.  Psychophysical measurement of rod and cone thresholds in stargardt disease with full-field stimuli.

Authors:  Frederick T Collison; Gerald A Fishman; J Jason McAnany; Jana Zernant; Rando Allikmets
Journal:  Retina       Date:  2014-09       Impact factor: 4.256

7.  CLINICAL CHARACTERIZATION OF STARGARDT DISEASE PATIENTS WITH THE p.N1868I ABCA4 MUTATION.

Authors:  Frederick T Collison; Winston Lee; Gerald A Fishman; Jason C Park; Jana Zernant; J Jason McAnany; Rando Allikmets
Journal:  Retina       Date:  2019-12       Impact factor: 4.256

8.  Intravitreal Use of a Bone Marrow Mononuclear Fraction (BMMF) Containing CD34+ Cells in Patients with Stargardt Type Macular Dystrophy.

Authors:  Carina Costa Cotrim; André M Vieira Messias; Rodrigo Jorge; Rubens Camargo Siqueira
Journal:  Stem Cells Int       Date:  2020-12-10       Impact factor: 5.443

Review 9.  The role of multimodal imaging and vision function testing in ABCA4-related retinopathies and their relevance to future therapeutic interventions.

Authors:  Saoud Al-Khuzaei; Mital Shah; Charlotte R Foster; Jing Yu; Suzanne Broadgate; Stephanie Halford; Susan M Downes
Journal:  Ther Adv Ophthalmol       Date:  2021-12-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.